Innoviva, Inc.

INVA US Health Care Pharmaceuticals
S&P 600
$20.66
+0.19%
Delayed · cached 15 min
Fair Value Analysis →

Price Chart

Price50-day avg200-day avg

How to read this: the line is the closing price over time. The two dashed lines are moving averages — the average price over the last 50 and 200 trading days — which smooth out daily noise to show the broader trend. Price above its moving averages reflects recent strength; below reflects recent weakness. Use the buttons to change the time range. Prices are end-of-day, not live.

Strengths

  • Low debt: debt-to-equity of 0.21.
  • Comfortable interest cover: operating profit covers interest about 9.8 times.
  • Return on equity is healthy at 22%.
  • Net profit margin is strong at 65.9%.
  • Current assets comfortably cover current liabilities (current ratio 14.64).

!Watch-points

  • Return on capital employed is on the lower side at 9.9%.

These points are generated automatically from the company’s reported figures to highlight what stands out. They are descriptive observations for educational purposes only — not advice or a recommendation to buy, sell, or hold.

Forensic Checks

Piotroski F-ScoreModerate
5 / 8

The F-Score adds one point for each of several year-on-year signs of improving profitability, lower leverage and better efficiency. Higher is generally stronger.

Based on 8 of the 9 signals — the rest need data not available for this stock.

These are well-known academic screening models, shown for educational context only. They describe historical financial patterns and are not predictions, advice, or a recommendation to buy, sell, or hold.

Key Ratios

Market Cap$1.49B
Current Price$ 20.66
High / Low$ 25.15 / 16.52
Stock P/E4.7935033
Book Value$ 16.80
Dividend Yield0%
ROCE9.91%
ROE21.99%
Debt to Equity0.21
Current Ratio14.64
P/B Ratio1.2168689
EPS$ 3.30
Debt$257.73M
PAT Margin65.92%
ICR9.81
Educational data only. Not a recommendation to buy, sell or hold any security.